Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review

被引：7

作者：

Tsigkas, Grigorios ^{[1
]}

Vakka, Angeliki ^{[1
]}

Apostolos, Anastasios ^{[1
,2
]}

Bousoula, Eleni ^{[3
]}

Vythoulkas-Biotis, Nikolaos ^{[1
]}

Koufou, Eleni-Evangelia ^{[1
]}

Vasilagkos, Georgios ^{[1
]}

Tsiafoutis, Ioannis ^{[4
]}

Hamilos, Michalis ^{[5
]}

Aminian, Adel ^{[6
]}

Davlouros, Periklis ^{[1
]}

机构：

[1] Univ Hosp Patras, Dept Cardiol, Patras 26504, Greece

[2] Natl & Kapodistrian Univ Athens, Hippocrat Gen Hosp, Dept Cardiol 1, Athens 15772, Greece

[3] Tzaneio Gen Hosp, Dept Cardiol, Piraeus 18536, Greece

[4] Red Cross Hosp, Dept Cardiol 1, Athens 11526, Greece

[5] Heraklion Univ Hosp, Dept Cardiol, Iraklion 71500, Crete, Greece

[6] Ctr Hospitalier Univ Charleroi, Dept Cardiol, B-6042 Charleroi, Belgium

来源：

JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE | 2023年 / 10卷 / 04期

关键词：

cancer; acute coronary syndrome (ACS); percutaneous coronary intervention (PCI); dual antiplatelet therapy (DAPT); triple antithrombotic therapy (TAT); atrial fibrillation (AF); cardiotoxicity; PERCUTANEOUS CORONARY INTERVENTION; PATENT FORAMEN OVALE; ANTITHROMBOTIC THERAPY; ANTICOAGULANT TREATMENT; ATRIAL-FIBRILLATION; OUTCOMES; DISEASE; CLOSURE; STROKE; BREAST;

D O I：

10.3390/jcdd10040135

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population.

引用

页数：16

共 50 条

[31] Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI [J].

Wang, Hao-Yu ;

Gao, Run-Lin ;

Xu, Bo ;

Yang, Yue-Jin ;

Yin, Dong ;

Wang, Yang ;

Dou, Ke-Fei .

PLATELETS, 2021, 32 (04) :533-541

[32] Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study [J].

Giustino, Gennaro ;

Kirtane, Ajay J. ;

Baber, Usman ;

Genereux, Philippe ;

Witzenbichler, Bernhard ;

Neumann, Franz-Josef ;

Weisz, Giora ;

Maehara, Akiko ;

Rinaldi, Michael J. ;

Metzger, Christopher ;

Henry, Timothy D. ;

Cox, David A. ;

Duffy, Peter L. ;

Mazzaferri, Ernest L. ;

Brodie, Bruce R. ;

Stuckey, Thomas D. ;

Gurbel, Paul A. ;

Dangas, George D. ;

Francese, Dominic P. ;

Ozan, Ozgu ;

Mehran, Roxana ;

Stone, Gregg W. .

AMERICAN JOURNAL OF CARDIOLOGY, 2016, 117 (12) :1877-1883

[33] DURATION OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE AFTER IMPLANTATION OF ENDOVASCULAR STENTS [J].

Sumarokov, A. B. ;

Buryachkovskaya, L., I ;

Lomakin, N., V ;

Dotsenko, Yu, V ;

Uchitel, I. A. ;

Timofeeva, L. A. .

KARDIOLOGIYA, 2018, 58 (01) :41-52

[34] Single Antiplatelet Therapy With Prasugrel vs. Dual Antiplatelet Therapy in Japanese Percutaneous Coronary Intervention Patients With High Bleeding Risk [J].

Nakamura, Masato ;

Kadota, Kazushige ;

Nakao, Koichi ;

Nakagawa, Yoshihisa ;

Shite, Junya ;

Yokoi, Hiroyoshi ;

Kozuma, Ken ;

Tanabe, Kengo ;

Akasaka, Takashi ;

Shinke, Toshiro ;

Ueno, Takafumi ;

Hirayama, Atsushi ;

Uemura, Shiro ;

Harada, Atsushi ;

Kuroda, Takeshi ;

Takita, Atsushi ;

Iijima, Raisuke ;

Murakami, Yoshitaka ;

Saito, Shigeru .

CIRCULATION JOURNAL, 2021, 85 (06) :785-+

[35] Use of Dual Antiplatelet Therapy Following Ischemic Stroke [J].

Dong, Junling ;

Wang, Fajun ;

Sundararajan, Sophia .

STROKE, 2020, 51 (05) :E78-E80

[36] Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study [J].

Hioki, Hirofumi ;

Kozuma, Ken ;

Kinoshita, Yoshihisa ;

Nanasato, Mamoru ;

Ito, Yoshiaki ;

Yamaguchi, Junichi ;

Shiode, Nobuo ;

Hibi, Kiyoshi ;

Tanabe, Kengo ;

Ako, Junya ;

Morino, Yoshihiro ;

Hirohata, Atsushi ;

Sonoda, Shinjo ;

Nakagawa, Yoshihisa ;

Okada, Hisayuki ;

Nakagami, Takuo ;

Takamisawa, Itaru ;

Ando, Kenji ;

Abe, Mitsuru ;

Ikari, Yuji .

JOURNAL OF CARDIOLOGY, 2021, 78 (02) :107-113

[37] Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis [J].

Han, Yan ;

Yuan, Xiaohang ;

Hu, Xin ;

Fang, Yan ;

Jiang, Mengting ;

Feng, Huanhuan ;

Gao, Lei .

CARDIOLOGY JOURNAL, 2023, 30 (04) :556-566

[38] Dual antiplatelet therapy duration and stent type in patients with high bleeding risk: A systematic review and network meta-analysis [J].

Saito, Tetsuya ;

Kuno, Toshiki ;

Fujisaki, Tomohiro ;

Gupta, Rahul ;

Hosseini, Kaveh ;

Takagi, Hisato ;

Wiley, Jose ;

Bangalore, Sripal .

AMERICAN HEART JOURNAL, 2025, 279 :9-19

[39] Previous hypertensive hemorrhage increases the risk for bleeding and ischemia for PCI patients on dual antiplatelet therapy [J].

Qiao, Manli ;

Bi, Qi ;

Fu, Paul ;

Wang, Yixin ;

Song, Zhe ;

Guo, Fang .

NEUROLOGICAL RESEARCH, 2017, 39 (06) :516-520

[40] Adding Precision to Defining Bleeding and Ischemic Risk With PCI in Cancer Patients [J].

Ky, Bonnie ;

Fanaroff, Alexander C. .

JACC-CARDIOVASCULAR INTERVENTIONS, 2021, 14 (10) :1106-1108

← 1 2 3 4 5 →